Ancilia Biosciences, a pioneering biotechnology firm specializing in harnessing CRISPR technology for bacterial therapies, announced today the successful closure of an $4.2 million financing round. Safar Partners led the investment, joined by Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures, and other institutional and private investors. The funding underscores the company’s commitment to leveraging CRISPR’s natural function to enhance the efficacy and utility of live bacterial products across therapeutic and industrial applications.
Ancilia Bio, known for its groundbreaking approach in applying CRISPR-Cas technology to confer immunity against viral bacteriophages in bacterial products, is led by co-founders Dr. Rodolphe Barrangou and Dr. David Paez-Espino. Dr. Barrangou, a CRISPR pioneer, discovered the natural immune system function of CRISPR in bacteria and holds the first CRISPR patent dating back to 2004. Together with Dr. Paez-Espino, who has contributed significantly to virology and bioinformatics, Ancilia Bio aims to revolutionize bacterial therapies by overcoming viral limitations that hinder product efficacy.
CEO Dr. Alexandra Sakatos expressed confidence in Ancilia’s innovative potential, stating, “This financing validates the uniqueness and promise of our technology. By harnessing CRISPR to bolster bacterial defenses against viral threats, we are poised to advance our therapeutic candidates into clinical trials. This funding will further strengthen our platforms and set the stage for upcoming milestones.”
Ancilia’s proprietary CoVE™ platform identifies and characterizes viral phages, enabling the company to develop live biotherapeutics and microbial products that are resilient against viral attacks. With proof-of-concept achievements and key patents secured, Ancilia Bio is at the forefront of transforming bacterial therapies for healthcare, industrial, and agricultural sectors.
In conjunction with the financing, Dr. Vera Schroeder from Safar Partners has joined Ancilia’s Board of Directors, citing the transformative potential of Ancilia’s technologies in healthcare and beyond.
Editorial Opinion: Ancilia Biosciences stands out in the biotechnology landscape with its innovative use of CRISPR-Cas technology to enhance bacterial therapies. By addressing viral limitations through its CoVE™ platform, Ancilia is positioned to lead advancements in live biotherapeutics, potentially revolutionizing healthcare treatments and industrial applications. The company’s strategic approach, coupled with strong scientific leadership, positions it favorably for future growth and impact.
For further information or corrections, please reach out to editor@thetimesmag.com
